Manufacturing of TPM suitable for human use
Active Awarded Last action
- Contract number
- 75N91023F00022
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,546,809
Award facts
- Contract value 100% obligated
- $1,546,809.00 Current and potential, with all options
- Completion date 62% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,546,809 |
About this award
The National Cancer Institute (NCI) awarded a $1.55M delivery order contract to Leidos Biomedical Research Inc. for the manufacturing of Tumor-Promoting Molecule (TPM) suitable for human use. The contract, awarded September 15, 2023, operates under a cost-plus-fixed-fee pricing structure with performance completion targeted for September 14, 2028, and will be executed at the contractor's Frederick, Maryland facility. This delivery order was issued without small business set-aside designation, reflecting the contractor's competitive standing as a large, established federal research partner.
Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and operates as a Federally Funded Research and Development Center (FFRDC) contractor with extensive experience supporting NCI and National Institutes of Health research initiatives. The company specializes in biomedical research support, clinical trial execution, and manufacturing of therapeutic agents, with a demonstrated track record of securing multi-year cost-plus-fixed-fee contracts from the NCI and related federal health agencies. This TPM manufacturing contract aligns with Leidos Biomedical Research's core capabilities in producing specialized scientific and medical compounds for government-supported research and development programs.
Quick answers
Who was awarded contract 75N91023F00022?
75N91023F00022 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023F00022 worth?
The government has obligated $1,546,809 on 75N91023F00022.
Is contract 75N91023F00022 an order under another contract?
Yes. 75N91023F00022 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00022 competed?
The extent of competition for 75N91023F00022 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award